About: Immunogenicity of Different Forms of Middle East Respiratory Syndrome S Glycoprotein

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immunogenicity of Different Forms of Middle East Respiratory Syndrome S Glycoprotein Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Immunogenicity of Different Forms of Middle East Respiratory Syndrome S Glycoprotein
Creator	Borisevich, S Dolzhikova, I Dzharullaeva, A Erokhova, A Gintsburg, A Gromova, A Grousova, D Loginova, S Logunov, D Naroditsky, B Ozharovskaia, T Popova, O Scherbinin, D Shcheblyakov, D Shmarov, M Tukhvatulin, A Zubkova, O
Source	Medline; PMC
abstract	The Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in 2012 during the first Middle East respiratory syndrome (MERS) outbreaks. MERS-CoV causes an acute lower-respiratory infection in humans, with a fatality rate of ~35.5%. Currently, there are no registered vaccines or means of therapeutic protection against MERS in the world. The MERS-CoV S glycoprotein plays the most important role in the viral life cycle (virus internalization). The S protein is an immunodominant antigen and the main target for neutralizing antibodies. In the present study, the immunogenicities of five different forms of the MERS-CoV S glycoprotein were compared: the full-length S glycoprotein, the full-length S glycoprotein with the transmembrane domain of the G glycoprotein of VSV (S-G), the receptor-binding domain (RBD) of the S glycoprotein, the membrane-fused RBD (the RBD fused with the transmembrane domain of the VSV G glycoprotein (RBD-G)), and the RBD fused with Fc of human IgG1 (RBD-Fc). Recombinant vectors based on human adenoviruses type 5 (rAd5) were used as delivery vehicles. Vaccination with all of the developed rAd5 vectors elicited a balanced Th1/Th2 response in mice. The most robust humoral immune response was induced after the animal had been vaccinated with the membrane-fused RBD (rAd5-RBD-G). Only immunization with membrane forms of the glycoprotein (rAd5-S, rAd5-S-G, and rAd5-RBD-G) elicited neutralizing antibodies among all vaccinated animals. The most significant cellular immune response was induced after vaccination of the animals with the full-length S (rAd5-S). These investigations suggest that the full-length S and the membrane form of the RBD (RBD-G) are the most promising vaccine candidates among all the studied forms of S glycoprotein.
has issue date	2019-01-01(xsd:dateTime)
bibo:pmid	31024747
has license	cc-by
sha1sum (hex)	24beb94c313a07be6b0c745a6ca8a3d810618506
resource representing a document's title	Immunogenicity of Different Forms of Middle East Respiratory Syndrome S Glycoprotein
has PubMed Central identifier	PMC6475872
has PubMed identifier	31024747
schema:publication	Acta Naturae
resource representing a document's body	covid:24beb94c313a07be6b0c745a6ca8a3d810618506#body_text
is schema:about of	named entity 'MERS-CoV' named entity 'studied' named entity 'MERS' named entity 'fused' named entity 'antigen' named entity 'Middle East respiratory syndrome' named entity 'T helper' named entity 'Middle East respiratory syndrome' named entity 'MERS-CoV' named entity 'RBD' named entity 'allophycocyanin' named entity 'DPP4' named entity 'vaccinated' named entity 'plays' named entity 'interferon gamma' named entity 'balanced' named entity 'The Middle' named entity 'fatality rate' named entity 'Glycoprotein' covid:arg/24beb94c313a07be6b0c745a6ca8a3d810618506 named entity 'fragment' named entity 'viral life cycle' named entity 'investigations' named entity 'VSV' named entity 'vector' named entity 'vaccines' named entity 'MERS-CoV' named entity 'severe acute respiratory syndrome' named entity 'FFU' named entity 'glycoprotein' named entity 'Middle East respiratory syndrome' named entity 'geometric' named entity 'compared' named entity 'acute' named entity 'vaccine' named entity '2012' named entity 'IFNγ' named entity 'domain' named entity 'coronavirus' named entity 'plaque-forming unit' named entity 'Th1' named entity 'humans' named entity 'domain' named entity 'IgG1' named entity 'membrane' named entity 'cellular immune response' named entity 'SARS' named entity 'VSV' named entity 'MERS-CoV' named entity 'neutralizing antibodies' named entity 'vectors' named entity 'glycoprotein' named entity 'MERS-CoV' named entity 'transmembrane domain' named entity 'glycoprotein' named entity 'viral particles' named entity 'recombinant vector' named entity 'glycoprotein' named entity 'RBD' named entity 'glycoprotein' named entity 'fatality rate' named entity 'IgG1' named entity 'SARS-CoV' named entity 'Middle East respiratory syndrome' named entity 'PBS' named entity 'MERS' named entity 'Middle East respiratory syndrome coronavirus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software